A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients With Late Onset Pompe Disease
Latest Information Update: 27 Mar 2025
At a glance
- Drugs Zocaglusagene nuzaparvovec (Primary)
- Indications Glycogen storage disease type II
- Focus Adverse reactions; First in man; Pharmacodynamics
- Acronyms FORTIS
- Sponsors Astellas Gene Therapies
Most Recent Events
- 05 Mar 2025 Planned End Date changed from 30 Nov 2029 to 28 Feb 2030.
- 05 Mar 2025 Planned primary completion date changed from 30 Nov 2029 to 28 Feb 2030.
- 05 Mar 2025 Status changed from recruiting to active, no longer recruiting.